The UR CTSI supports Incubator projects that accelerate scientific discovery in the life sciences and public health, leading to new independently funded research programs. Each award is funded at a maximum level of $100,000 per year for two years. Faculty from all UR schools are eligible to apply.
Like traditional program project grants, Incubator projects should consist of two or more individual pilot projects, led by collaborating investigators and linked by a scientific or clinical theme. The goal of the program is to identify research collaborations with potential to deliver a quantum advance in therapies, diagnostic techniques or population and public health programs—ultimately leading to extramural program project funding. An assigned project officer will serve as a link between the UR CTSI, funded investigators and other appropriate resources throughout the duration of the research project.
Solicitation and Review Process
Phase 1: Applicants submit two-page abstracts summarizing their proposals. A UR CTSI Review Committee composed of selected experts will evaluate, score and discuss all preliminary applications.
Phase 2: A subset of applicants will be invited to submit full proposals. The UR CTSI Review Committee will engage in a formal study section-style discussion and scoring meeting. Funding recommendations go to the UR CTSI Executive Team for final approval.
CTSI Cost Sharing Information
CTSI Signoff Form
View the 2021 RFA for the Incubator Program
August 16, 2021
The following dates apply to the most recent solicitation:
- September 20, 2021, at 5:00 p.m. – Initial abstracts of proposals must be received. Please note that the online submission system will reject proposals submitted after 5:00 p.m.
- November 15, 2021 – Applicants from whom full proposals will be solicited will be notified.
- January 18, 2022, at 5:00 p.m. – Full proposals must be received.
- March 14, 2022 – Notifications of Award will be made. Awarded proposals must meet several requirements prior to the start date. See the "Requirements if funds are awarded" section of the RFA for details.
- July 1, 2022 – The anticipated start date.
Note: All animal and human subject protocols must be approved prior to the start date. No funds for research project costs may be released until all required human subjects and animal welfare approvals have been received.
The Incubator Funding Attestation must be submitted with the initial abstract and full proposal.
UR241-2: A novel interleukin-1 receptor-associated kinase 4 inhibitor for cancer treatment
Michael Becker, M.D.
Dean's Professor of Hematology/Oncology in the Wilmot Cancer Institute